Shaily Engineering Plastics LtdQ2 FY23
Shaily Engineering Plastics Ltd Q2 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹2,850P/E: 89.5Market Cap: ₹12.7K CrSector: Consumer Durables
Management growth scorecard
Revenue
Category 1
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 1- →Targeting a 60-70% growth in healthcare revenue for the current financial year, indicating a substantial ramp-up in the pharma segment.
- →Expecting to double overall revenue in the next 3 years, supported by increased capacity and new product launches.
- →Pharma business projected to grow faster than the overall business, leading to margin improvement over a 3-year horizon.
- →Adding capacity to manufacture an additional 20 million pens, with volume ramp-up expected over FY '24 to FY '26.
- →Gradual improvement in utilization levels anticipated:
- → - Current utilization expected around 50-55% for FY '24, with gradual improvement over the year.
- → - Full utilization of new pharma facilities likely by second half of FY '25.
- →New orders and products (e.g., GE Appliances, home furnishing) to contribute to growth starting Q4 FY '24 and FY '25.
- →UK subsidiary foresees 2-3x revenue growth in the current financial year.
Margin guidance
Category 3- →The company anticipates significant growth, targeting approximately 60% growth in the healthcare (pharma) business for the current financial year (FY '24), with sustainable margin improvements expected as this segment expands.
- →Revenue from the pharma business is expected to double over a three-year horizon (by FY '26/'27) driven by new capacity and increased volume.
- →New business wins, including from longstanding client GE Appliances and home furnishings, are expected to contribute incremental revenue starting Q4 FY '24 and Q1 FY '25.
- →Overall EBITDA margins have shown improvement, with a 290 bps increase in Q1 FY '24, and further margin enhancement is expected over a 3-year perspective as pharma business grows.
- →Utilization levels are projected to improve gradually; around 50-55% utilization expected in FY '24 with further increases in FY '25, supporting improved profitability.
- →Earnings growth is guided by doubling revenues in key segments and improved operational efficiencies rather than per-ton gross profit targets.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript from the Q1 FY24 earnings call.
- →Discussions focused on existing investments, capacity expansions, and business growth rather than new funding rounds.
- →The company has already utilized funds raised in 2021 for enhancing capacities and building new healthcare facilities.
- →No guidance or indication was provided about seeking additional debt or equity financing in the near term.
Order book
- →Awarded new business from General Electric (GE Appliances) valued at INR 40 crores per annum; signifies a strong and long-standing relationship since 1995 with growing opportunities.
- →Received business confirmations for 3 new home furnishing products, totaling INR 50 crores per annum, enhancing relationship and utilization.
- →Added 3 new products in the automotive and engineering segments contributing to growth.
- →Incremental business of INR 90 crores expected to flow in from Q4 FY '24 and Q1 FY '25 onwards, accretive at EBITDA level without significant incremental capex.
- →Focus on building new strategic businesses in healthcare, consumer electronics, and industrial applications, with some projects in early stages.
- →The company refrains from giving precise utilization or revenue guidance for orders but anticipates gradual growth and ramp-up over 18 to 30 months horizon.
Capex plans
Yes- →Current year capex primarily focused on pharma facility and tool room; no large capex beyond this planned for the current year. (Page 17)
- →Major pharma capex expected to complete between Q2 and Q3 of FY '24. (Page 8)
- →Ramp-up of pharma facility expected over the next 4 to 6 quarters, with full utilization likely by the second half of FY '25. (Page 8)
- →Post-improvement in utilization, future capex plans will depend on how utilization levels improve in other business segments. (Page 17)
- →No incremental tooling capex anticipated for the INR 90 crore incremental orders; these orders are accretive at EBITDA and ROCE levels. (Page 15)
- →Pharma investments made recently are aimed at accelerating faster revenue growth with increased IP contribution. (Pages 3, 8)
How does Shaily Engineering Plastics Ltd rank vs peers in Consumer Durables?
Pro feature1Shaily Engineering Plastics Ltd
Rev 1Mar 3
See full Consumer Durables sector rankings
Want more stocks like Shaily Engineering Plastics Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio